ROME, Sept. 23 (Xinhua) -- Italian medical diagnostics company DiaSorin announced on Wednesday that it has reached a binding agreement with the government of Baoshan District in the north of Shanghai, the biggest city in China, on establishing its first manufacturing and research site there.
DiaSorin has been operating in China in a joint venture with the local government for over 10 years. It currently serves over 1,000 hospitals in the country for the diagnosis of prenatal infections, the statement said.
Once the new plant in Shanghai is completed, DiaSorin will employ over 300 people there, the Italian company said.
"We strongly believe that a stronger local presence will allow us to... access tremendous new market opportunities," commented Chen Even, chief commercial officer (CCO) of the DiaSorin Group.
"Our presence in China has significantly increased since 2005, when we started to operate in the country," commented Carlo Rosa, chief executive officer (CEO) of the DiaSorin Group. "We think that the time has come to grow further in this important market."
Rosa added that "it is strategic for us to ...strengthen our presence in growing and strategic markets like China, where hundreds of billions of dollars will be invested by the government in the next 10 years to further improve the health care system."
Headquartered in Italy, DiaSorin develops, produces and markets reagent kits used by diagnostics laboratories worldwide. Enditem
A single purchase
